Home › Trial NCT06716658
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
- Trial IDNCT06716658
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorInstitute of Hematology & Blood Diseases Hospital, China
- Enrollment48
- Start date2024-12-25
- ConditionsLymphoma, T-Cell · NK-LGL Leukemia · T-LGL Leukemia · Cutaneous T Cell Lymphoma · Cutaneous T Cell Lymphoma (CTCL) · Large Granular Lymphocyte Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.